Logo - springer
Slogan - springer

| Drugs in R&D (Editorial Board)

Drugs in R&D

Drugs in R&D

Editor: Anton van Rensburg

ISSN: 1174-5886 (print version)
ISSN: 1179-6901 (electronic version)

Journal no. 40268

G. An, Orlando, FL, USA

R.K. Campbell, Pullman, WA, USA

D. Cattaneo, Milan, Italy

G. Cherala, Portland, OR, USA

Y.K. Gupta, New Delhi, India

H.P. Hartung, Dusseldorf, Germany

C. Höcht, Buenos Aires, Agentina

N.M. Idkaidek, Amman, Jordan

F. Jamali, Edmonton, Alberta, Canada

T.K.L. Kiang, Vancouver, Canada

S.  Perez-Lloret, Paris, France

M.J. McKeage, Auckland, New Zealand

P.J. Nathan, Cambridge, UK

B.M. Patel, Ahmedabad, India

M. Pfister, Basel, Switzerland

G. Remington, Toronto, ON, Canada

M.H. Shishehbor, Cleveland, OH, USA

L.P. Shulman, Chicago, IL, USA

L. Tóthfalusi, Budapest, Hungary

R. Vats, Hyderabad, India

J. Weiss, Heidelberg, Germany





For authors and editors

  • Aims and Scope

    Aims and Scope


    Drugs in R&D is an international, peer reviewed, open access, online only journal, and provides timely information from all phases of drug research and development that will inform clinical practice. Healthcare decision makers are thus provided with knowledge about the developing place of a drug in therapy.

    The Journal includes: 

    ·        Clinical research on new and established drugs;

    ·        Preclinical research of direct relevance to clinical drug development;

    ·        Short communications and case study reports that meet the above criteria will also be considered.

    Letters to the editor are welcomed and will be considered for publication. Reviews may also be considered. All manuscripts are subject to peer review by international experts.

  • Submit Online
  • Instructions for Authors

    Instructions for Authors


  • Conflict of Interest statement (pdf, 423...
  • Copyright information

    Copyright information


    Copyright and Licence Agreement

    Open Access Drugs in R&D is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, go to: http://creativecommons. org/licenses/by-nc/4.0

    Journal ownership: Springer International Publishing Switzerland

    Copyright of articles: © The Author(s)

Alerts for this journal


Get the table of contents of every new issue published in Drugs in R&D.

Additional information